{"id":"atm-kinase-inhibitor-azd1390","safety":{"commonSideEffects":[{"rate":"30%","effect":"Fatigue"},{"rate":"20%","effect":"Nausea"},{"rate":"15%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZD1390 is a potent and selective inhibitor of ataxia-telangiectasia mutated (ATM) kinase, which plays a critical role in the DNA damage response pathway.","oneSentence":"ATM kinase inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:56:00.930Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma"}]},"trialDetails":[{"nctId":"NCT06894979","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-06-18","conditions":"Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma","enrollment":54},{"nctId":"NCT05182905","phase":"EARLY_PHASE1","title":"AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nader Sanai","startDate":"2022-05-27","conditions":"Glioblastoma, Glioma, Glioblastoma Multiforme","enrollment":97},{"nctId":"NCT05116254","phase":"PHASE1","title":"Sarcomas and DDR-Inhibition; a Combined Modality Study","status":"TERMINATED","sponsor":"The Netherlands Cancer Institute","startDate":"2022-07-18","conditions":"Soft Tissue Sarcoma Adult","enrollment":12},{"nctId":"NCT03423628","phase":"PHASE1","title":"A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2018-04-02","conditions":"Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant","enrollment":180},{"nctId":"NCT04550104","phase":"PHASE1","title":"A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC","status":"RECRUITING","sponsor":"University of Leeds","startDate":"2021-03-17","conditions":"Non Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT03970447","phase":"PHASE2, PHASE3","title":"A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Global Coalition for Adaptive Research","startDate":"2019-07-30","conditions":"Glioblastoma","enrollment":1280},{"nctId":"NCT05678010","phase":"PHASE1","title":"A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-05-17","conditions":"Solid Tumor, Metastatic Solid Tumor, Solid Carcinoma","enrollment":54},{"nctId":"NCT03215381","phase":"PHASE1","title":"AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-10","conditions":"Healthy Volunteer Male Subjects","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AZD-1390","AZD1390"],"phase":"phase_1","status":"active","brandName":"ATM Kinase Inhibitor AZD1390","genericName":"ATM Kinase Inhibitor AZD1390","companyName":"Children's Oncology Group","companyId":"children-s-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATM kinase inhibitor Used for Glioblastoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}